[go: up one dir, main page]

WO1999064029A1 - Extrait vegetal - Google Patents

Extrait vegetal Download PDF

Info

Publication number
WO1999064029A1
WO1999064029A1 PCT/US1999/012931 US9912931W WO9964029A1 WO 1999064029 A1 WO1999064029 A1 WO 1999064029A1 US 9912931 W US9912931 W US 9912931W WO 9964029 A1 WO9964029 A1 WO 9964029A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
patient
plant extract
effective amount
steps
Prior art date
Application number
PCT/US1999/012931
Other languages
English (en)
Inventor
Hanoch Kosovsky
Original Assignee
Mayamedic International, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayamedic International, Llc filed Critical Mayamedic International, Llc
Priority to AU45550/99A priority Critical patent/AU4555099A/en
Publication of WO1999064029A1 publication Critical patent/WO1999064029A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention relates to a therapeutic preparation comprising a plant extract and medical use thereof.
  • Viral diseases such as AIDS, influenza, hepatitis, and genital herpes and papilloma and other diseases such as diabetes, macular degeneration, and emphysema, and skin and hair conditions are major health concerns. These diseases contribute greatly to morbidity, mortality, and the generalized discomfort of patients worldwide.
  • Medicinal products obtained from a variety of plants are currently being used or under investigation in the treatment of many diseases.
  • numerous compounds obtained from plant extracts are under investigation for the treatment for cancer, (e.g., Fujioka, et al. 1999. "Antiproliferative constituents from umbelliferae plants. V. A new furanocoumarin and falcarindiol furanocoumarin ethers from the root of Angelica japonica," Chem Pharm Bull (Tokyo) 47:96-100; Ren, et al. 1999.
  • Extract of Solanum muricatum (Pepino/CSG) inhibits tumor growth by inducing apoptosis," Anticancer Res 19:403-408; Yoon, et al. 1999.
  • Plant extracts obtained from plants of the Bactris genus preferably Bactris balanoidea plants have been found to provide therapeutic effects against viral diseases and a variety of other diseases.
  • the invention relates to a method for isolating a therapeutic plant extract by combining Bactris plants or portions thereof with a nontoxic solvent appropriate for solubilizing the plant extract from the plants or plant portions and recovering the plant extract.
  • the plants are Bactris balanoidea, and more preferably, the plant portions are the roots of the plant.
  • the plants or portions thereof can be in dry powder form prior to making the extract.
  • the plant extract can also be extracted from the plants or portions thereof by boiling in the nontoxic solvent.
  • the invention relates to a plant extract of the present invention made by combining Bactris plants or portions thereof with a nontoxic solvent appropriate for solubilizing the plant extract from the plants or plant portions and recovering the plant extract.
  • the plant extract is made from Bactris balanoidea, and more preferably, the plant extract is made from the roots of the plant.
  • the plant extract can also be extracted from the plants or portions thereof by boiling in the nontoxic solvent.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a plant extract of the present invention.
  • the present invention relates to a pharmaceutical preparation in dosage unit form adapted for administration to obtain a therapeutic effect, comprising, per dosage unit, a therapeutically effective amount of the plant extract of the present invention.
  • the therapeutically effective amount of the plant extract in the pharmaceutical preparation in dosage unit form is from about 100 milligrams to about 500 milligrams per kilogram body weight.
  • the invention relates to a method for preparation of a raw plant powder made by drying the Bactris plants or portions thereof in the absence of direct sunlight, and then pulverizing the dried plants or portions thereof to form a raw plant powder.
  • the raw plant powder is made from Bactris balanoidea, and more preferably, from the roots of the plant.
  • the moisture content of the plants or portion thereof is reduced to from about 5% to about 10% prior to pulverizing.
  • the invention relates to a raw plant powder of the present invention made by drying the Bactris plants or portions thereof in the absence of direct sunlight, and then pulverizing the dried plants or portions thereof to form a raw plant powder.
  • the raw plant powder is made from Bactris balanoidea, and more preferably, from the roots of the plant.
  • the moisture content of the plants or portion thereof is reduced to from about 5% to about 10% prior to pulverizing.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the raw plant powder of the present invention.
  • the invention relates to a pharmaceutical preparation in dosage unit form adapted for administration to obtain a therapeutic effect, comprising, per dosage unit, a therapeutically effective amount of the raw plant powder of the present invention.
  • the therapeutically effective amount of the raw plant powder in the pharmaceutical preparation in dosage unit form is from about 2 milligrams to about 30 milligrams.
  • the invention relates to a plant extract made by boiling a therapeutic amount of the raw plant powder of the present invention in an aqueous solvent to form an aqueous solution.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the plant extract made from the raw plant powder of the present invention.
  • the invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising a plant extract made from the raw plant powder of the present invention.
  • the invention relates to a pharmaceutical preparation in dosage unit form adapted for administration to obtain a therapeutic effect, comprising, per dosage unit, a therapeutically effective amount of the plant extract made from the raw plant powder of the present invention.
  • the therapeutically effective amount of the plant extract in the pharmaceutical preparation in dosage unit form is from about 100 milligrams to about 500 milligrams per kilogram body weight.
  • the invention relates to the first medical use of the plant extract of the present invention for treatment of diabetes, acquired immunodeficiency syndrome, influenza, common cold symptoms, pulmonary emphysema, bronchitis, poliomyelitis, macular degeneration, cancer, gingivitis, dermatitis, hair loss, hepatitis, genital herpes, papilloma, and asthma.
  • the invention relates to the first medical use of the raw plant powder of the present invention for treatment of diabetes, acquired immunodeficiency syndrome, influenza, common cold symptoms, pulmonary emphysema, bronchitis, poliomyelitis, macular degeneration, cancer, gingivitis, dermatitis, hair loss, hepatitis, genital herpes, papilloma, and asthma.
  • the invention relates to a method of treatment for diabetes, acquired immunodeficiency syndrome, influenza, common cold symptoms, pulmonary emphysema, bronchitis, poliomyelitis, macular degeneration, cancer, gingivitis, dermatitis, hair loss, hepatitis, genital herpes, papilloma, and asthma in a patient, comprising the steps of administering an effective amount of the plant extract of the present invention.
  • the invention relates to a method of treatment for diabetes, acquired immunodeficiency syndrome, influenza, common cold symptoms, pulmonary emphysema, bronchitis, poliomyelitis, macular degeneration, cancer, gingivitis, dermatitis, hair loss, hepatitis, genital herpes, papilloma, and asthma in a patient, comprising the steps of administering an effective amount of the raw plant powder of the present invention.
  • Fig. 1 is a graph depicting the average body weight in grams of untreated mice and mice treated with the plant extract of the present invention over time. Treatment with the plant extract was maintained throughout the experiment, and diabetes was induced on Day 12 by administration of streptozotocin.
  • Fig. 2 is a graph depicting the average food intake in grams/mouse/day for untreated mice and mice treated with the plant extract of the present invention over time. Treatment with the plant extract was maintained throughout the experiment, and diabetes was induced on Day 12 by administration of streptozotocin.
  • Fig. 3 is a graph depicting the average fluid intake in milliliters/mouse/day for untreated mice and mice treated with the plant extract of the present invention over time. Treatment with the plant extract was maintained throughout the experiment, and diabetes was induced on Day 12 by administration of streptozotocin.
  • Fig. 4 is a graph depicting the average blood plasma glucose concentration in mmol/liter grams/mouse/day for of untreated mice and mice treated with the plant extract of the present invention over time. Treatment with the plant extract was maintained throughout the experiment, and diabetes was induced on Day 12 by administration of streptozotocin.
  • Fig. 5 A and 5B are graphs depicting the effect of the plant extract of the present invention on the treatment of a patient with Type 2 diabetes on blood glucose concentration over time.
  • Fig. 5 A depicts a first 11 -week treatment regime begun late 1998. Treatment with the plant extract began at Day 10 and was discontinued at Day 51.
  • Fig. 5B depicts a second 9- week treatment regime begun in January, 1999. Treatment with the plant extract began at Day 7 and discontinued at Day 49.
  • Therapeutic plant extracts have been obtained from Bactris plants, preferably Bactris balanoidea, also known as viscoyol, which ranges from Central to South America.
  • Bactris balanoidea also known as viscoyol
  • the therapeutic composition in the plant extract has been found in the roots and fruit of the plant, and it is believed that other parts of the plant, including but not limited to leaves and stems, also contain the therapeutic composition.
  • the plant extract is obtained from the roots because of their year-round accessibility.
  • the plant extract of the present invention is extracted from the plant or portions thereof in a nontoxic solvent appropriate for solubilizing the plant extract from the plant or portions thereof.
  • the nontoxic solvent is aqueous. More preferably, the solvent is water.
  • the extraction process in the nontoxic solvent is accelerated by increased temperatures.
  • the plant or portions thereof are boiled in the nontoxic solvent.
  • the plant extract of the present invention is preferably extracted from the roots by boiling to form an aqueous solution, e.g., about 454 grams of roots boiled in about 7.6 liters of water. The roots can be dried and then cut into shavings or ground to a coarse powder prior to boiling.
  • the subsequent solution can then be freeze-dried to provide an active powder (hereinafter referred to as “freeze-dried powder”).
  • a raw plant powder is prepared from the plants or portions thereof (hereinafter referred to as “raw plant powder"), by drying the plants or portions thereof and then pulverizing the plants or portions thereof into a powder.
  • a preferred method for preparing the powder from dried roots comprises the following steps: (1) cleaning fresh Bactris roots by washing and scrubbing; (2) disinfecting the roots, preferably in sulfur dioxide (SO 2 ) solution; (3) cutting the roots into shavings; (4) drying shavings in the absence of direct sunlight to prevent loss of potency upon exposure to direct sunlight; (5) drying the shavings further in a drying apparatus such as a kiln set at about 60°C to about 100°C, preferably at 65°C, to reduce the moisture content of the shavings to about 5% to about 10%, preferably to about 6%, and to disinfect the shavings; and (6) pulverizing and sifting the shavings to form a powder.
  • a drying apparatus such as a kiln set at about 60°C to about 100°C, preferably at 65°C, to reduce the moisture content of the shavings to about 5% to about 10%, preferably to about 6%, and to disinfect the shavings.
  • disinfectants which are useful in food preparation or as food additives, ultraviolet light, and/or ozone can be used to disinfect the roots, shavings, and/or powder. It is desirable to reduce the moisture content of the shavings sufficiently to make the shavings pulverizable and also so as to deter subsequent antimicrobial contamination by bacteria or fungi.
  • the freeze-dried powder and raw powder are preferably vacuum-packed in a light resistant container to increase shelf life by limiting the exposure of the powder to humidity and sunlight.
  • the powders are processed into capsules or tablets which are stored in light resistant containers. Other containers may be used and packaged, handled, and stored appropriately to provide light and/or humidity protection.
  • the plant extract or raw plant powder of the present invention can be administered topically, orally, sublingually, or as an inhalant. It can be administered via ingestion of a food substance containing the plant extract in an amount sufficient to achieve therapeutic levels. Alternatively, it can be enclosed in capsules, compressed into tablets, micro-encapsulated, entrapped in liposomes, in solution or suspension, alone or in combination with a substrate immobilizing material such as starch or poorly absorbable salts. Pharmaceutically compatible binding agents and/or adjuvant materials can be used as part of a composition.
  • Tablets or capsules can contain any of the following ingredients, or compounds of similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; and excipient such as starch or lactose; an integrating agent such as alginic acid; corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; and sweetening and flavoring agents.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • excipient such as starch or lactose
  • an integrating agent such as alginic acid
  • corn starch a lubricant such as magnesium stearate
  • a glidant such as colloidal silicon dioxide
  • sweetening and flavoring agents When a capsule form is used, a fatty oil can be used as the liquid carrier.
  • Capsules and tablets can be coated with sugar, shellac and other enteric agents as is known.
  • the plant extract can also be in
  • An effective therapeutic amount of the freeze-dried plant extract powder of the present invention is from about 100 to about 500 milligrams per kilogram body weight.
  • the preferred therapeutic dosage is from about 100 to about 200 milligrams per kilogram body weight.
  • the preferred therapeutic dosage is from about 300 to about 500 milligrams per kilogram body weight.
  • the effective therapeutic amount is from about 2 grams to about 30 grams, more preferably from about 4 grams to about 15 grams.
  • the recommended daily therapeutic amount of the plant extract of the present invention can be given in one dose. However, it is preferred that the therapeutic amount be divided into two to four portions, with the portions taken periodically throughout the day .
  • Example 1 Treatment for Diabetes
  • the plant extract of the present invention has been shown to provide therapeutic effects in the treatment of diabetes.
  • the effect of glucose homeostasis of the plant extract used as a treatment for diabetes mellitus was evaluated in a blind study carried out by an independent laboratory, using normal and streptozotocin diabetic mice.
  • mice were used in an acute toxicity evaluation, and mice (in bred) were used in an anti-diabetes study.
  • the test animals were housed at 22 ⁇ 2°C in an air-conditioned room and supplied with a standard pellet diet and water ad libitum.
  • the rats were observed continuously for ten hours, and the percentage mortality over a 24 hour period was recorded. The changes in various autonomic and behavioral responses were noted.
  • the LD 50 was calculated by probit analysis.
  • the treated animals In the acute toxicity test, the treated animals exhibited no signs of toxicity, and no mortality was observed up to the 900 milligrams per kilogram body weight dose level. At eight hours after the injection of 2100 milligrams of plant extract per kilogram body weight, 100% death was observed. Before death, most of the rats showed imbalance, crawling gait, twitching, and tremor. The acute toxicity concentration at which 50% of the rats were killed within 24 hours (LD 50 ) was 1533 milligrams per kilogram body weight.
  • mice In the anti-diabetes study, groups of 5-7 normal mice were subjected to a four day run-in period followed by treatment with a decoction containing 192 milligram of plant extract per kilogram body weight by gavage beginning on Day 1. Treatment with 192 milligrams per kilogram body weight was given daily throughout the experiment. Diabetes was induced on Day 12 by administration of streptozotocin (Sigma Chemical Co, St. Louis, Mo.) at 200 milligrams per kilogram body weight i.p. in 0.5 mol/L citrate buffer, pH 4.5. Body weight, food and fluid uptake were monitored daily. Blood samples (50 microliters) for plasma glucose were obtained from the tail tip of conscious mice on Days -4, 3, 10, 12, 17, 24, 30, and 40.
  • treatment with the plant extract did not alter any of the parameters measured (body weight, food and fluid intake, and basal plasma glucose) during the administration to normal mice.
  • Induction of diabetes with streptozotocin was associated with the characteristic development of hyperglycemia, hyperphagia, polydipsea, and loss of body weight.
  • Treatment with the plant extract lowered mean values for basal plasma glucose concentration in the diabetic mice, and achieved statistical significance when compared with the basal plasma glucose concentration of the control group.
  • the plant extract also reduced fluid intake and body weight loss in the diabetic mice.
  • the plant extract of the present invention reduced the hyperglycemia of streptozotocin diabetic mice and also generally reduced the polydipsea and loss of body weight.
  • Table I Average Body Weight (grams) of Treated vs. Untreated Mice Over Time
  • Table II Average Food Intake (grams/mouse/day) of Treated vs. Untreated Mice Over Time
  • Table III Average Fluid Intake (milliliters/mouse/day) of Treated vs. Untreated Mice Over Time
  • Table IV Average Plasma Glucose (mmol/liter) of Treated vs. Untreated Mice Over Time
  • An exemplary case report for a patient with Type 2 diabetes treated with the plant extract indicates that the plant extract of the present invention is capable of reducing and maintaining low blood glucose concentrations in Type 2 diabetes.
  • a 36-year old Latin male was diagnosed with Type 2 diabetes. He exhibited all of the signs of Type 2 diabetes such as obesity, lack of exercise, and poor diet control, and had been unable to maintain his blood glucose concentrations at normal levels.
  • the patient monitored his blood glucose levels on a daily basis with a calibrated glucometer and was on a physician prescribed daily regimen of oral anti- diabetic for approximately 3.5 years in an attempt to control his blood sugar levels, with only moderate success.
  • Glucotrol and glucophage While taking two separate oral anti-diabetic daily, Glucotrol and glucophage, at a high dosage level, his blood glucose concentration fluctuated between 190-280 mg/dl, well above normal.
  • the patient began a second treatment regimen of the plant extract of the present invention, using it over a 4- week period.
  • the patient's blood sugar levels were reduced almost to normal levels and were maintained at those levels as long as he continued to take the plant extract.
  • his blood sugar levels started to rise.
  • the plant extract was capable of reducing and maintaining low blood glucose concentrations in Type 2 diabetes as long as the treatment was continued.
  • Example 2 Treatment for AIDS
  • the plant extract of the present invention has been shown to provide therapeutic effects in the treatment of acquired immunodeficiency syndrome (AIDS) patients.
  • a plant extract solution was prepared by boiling about 454 grams of dried Bactris balanoidea root shavings in about 7.6 liters of water.
  • One to 1 V% glasses of the solution (approximately 100-200 mg of the plant extract/glassful) were ingested morning and evening by over 100 AIDS patients. Good results were observed by the attending physician.
  • the CD4+ count increased to 486, 450, 460, and 360, compared to a normal CD4+ of 400, indicating an improvement in immunocompetence.
  • a test for human immunodeficiency virus on one of the patients changed from positive to negative after treatment with the plant extract.
  • An exemplary case report for a patient diagnosed with GRID indicates that the plant extract of the present invention has a marked multiple positive therapeutic effect in AIDS.
  • the patient was originally diagnosed with GRID in 1989, before the causative agent of AIDS was discovered. He was a long term survivor, having apparently been infected with the human immunodeficiency virus for over 20 years. Laboratory documentation of his infection was carried out in 1985, and he was treated with various regimens of drugs over the past few years, including nucleoside inhibitors and protease inhibitors. His viral load count, a primary indicator of disease status reached as high as 4,900,000 copies (1993) and his CD4+ lymphocyte count, another disease-status indicator, fell to as low as 30. With the advent of combination therapy, the patient regained some of his immune function and showed a reduction in viral load.
  • the combination therapy did not sustain its effect and, early in 1999, he began to fail clinically.
  • the patient began taking two times daily the plant extract of the present invention prepared by boiling 3 grams of the dried plant extract in 237 milliliters of water per dose.
  • the patient showed remarkable recovery in CD4+ count and a marked decrease in viral load as given in Table V below.
  • the patient reported a marked reduction in fat deposits and residual fatty tissue, elimination of paresthesia of the lower limbs and feet, elimination of Grade 3 neuropathy, and an overall increase in energy and quality of life, indicating the plant extract of the present invention has a marked multiple positive therapeutic effect in AIDS.
  • the plant extract of the present invention has been shown to provide therapeutic as well as prophylactic effects against influenza and the common cold.
  • a plant extract solution was prepared by boiling about 454 grams of the roots of interest in about 7.6 liters of water. Voluntary patients diagnosed with influenza ingested daily two to three glasses of the plant extract solution (approximately 100-200 mg of the plant extract /glassful). Within two days, all patients were symptom-free.
  • Treatment with the plant extract of the present invention has shown positive improvement in patients suffering from pulmonary emphysema.
  • 14 patients suffering pulmonary emphysema were treated with a tea preparation as follows: 2-3 grams of the dried plant extract of the present invention were gently boiled in approximately 237 milliliters of water, and each patient received 473-711 milliliters per day.
  • Treatment with the tea preparation resulted in 95% reduction of symptoms in the emphysema patients after 15 days of administration.
  • Example 5 Treatment for Bronchitis Treatment with the plant extract of the present invention has shown positive improvement in patients suffering from bronchitis.
  • Example 6 Treatment for Poliomyelitis Treatment with the plant extract of the present invention has shown positive improvement in a patient suffering from poliomyelitis.
  • the patient was treated with a tea preparation as follows: 2-3 grams of the dried plant extract of the present invention were gently boiled in approximately 237 milliliters of water, and the patient received 473-711 milliliters per day.
  • Example 7 Treatment for Macular Degeneration Patients suffering from age-related macular degeneration have shown significant improvements in vision and relief from the symptoms of dry eyes after being treated with ophthalmic drops of the plant extract. In a study of nine patients, ophthalmic drops were prepared by boiling about 454 grams of the roots of interest in about 7.6 liters of water. After filtering, two to three drops of the plant extract solution were administered to each eye once a day. The results of this study are summarized for each patient.
  • Patient #2 was a 72 year old male diagnosed with pseudophakia OU, age related macular degeneration, bullous keratopathy of the left eye, and failed keratoplasty of the left eye.
  • the patient's visual acuity measured OD 20/70, indicating definite improvement.
  • Patient #4 was an 80 year old female who was diagnosed as having age related macular degeneration, and fundus examination showed advanced macular degeneration with scar formation.
  • a patient with macular degeneration was treated with a tea preparation as follows: 2-3 grams of the dried plant extract of the present invention were gently boiled in approximately 237 milliliters of water, and each patient received 473-711 milliliters per day. The patient with macular degeneration of the eye was cured, with complete reversal of symptoms and regained eyesight.
  • Example 8 Inhibition of Cancer Cells Cancer cell preparations were treated in vitro with the plant extract of the present invention. Complete inhibition of lung cancer, breast cancer, and two types of thyroid cancer cells was achieved.
  • Example 9 Treatment for Gingivitis
  • the plant extract of the present invention has been shown to provide therapeutic effects against gingivitis.
  • a patient suffering from gingivitis and subsequent loss of teeth began voluntary treatment with the plant extract.
  • the plant extract solution was prepared by boiling about 454 grams of the roots of interest in about 7.6 liters of water.
  • Two glasses of the plant extract solution (approximately 100-200 mg of the plant extract/glassful) was ingested daily, and the mouth was rinsed twice daily with the plant extract solution. Upon evaluation, the patient's periodontal problem was reported to have abated.
  • Example 10 Treatment for Dermatitis
  • a plant extract solution was prepared by boiling about 454 grams of the roots of interest in about 7.6 liters of water. This solution was applied to the skin several times a day.
  • a lotion was also prepared by concentrating the plant extract solution by a factor of 20 and mixing the concentrate with an inert body lotion. The lotion was applied to the skin twice daily.
  • Example 11 Treatment for Hair Loss External application of the plant extract of the present invention on the bald head of one patient resulted in hair growth.
  • Two forms of topical administration were successfully used.
  • a plant extract solution was prepared by boiling about 454 grams of the roots of interest in about 7.6 liters of water. This solution was applied to the scalp several times a day.
  • a lotion was also prepared by concentrating the plant extract solution by a factor of 20 and mixing the concentrate with an inert body lotion. The lotion was applied to the scalp twice daily.
  • the patient also ingested two glasses of the plant extract solution (approximately 100-200 mg of the plant extract/glassful) daily.
  • Example 12 Other Treatments Treatment with the plant extract of the present invention has shown positive improvement in patients suffering from hepatitis (A, B, and C), genital herpes, papilloma, and asthma.
  • the plant extract solution was prepared by boiling about 454 grams of the roots of interest in about 7.6 liters of water. Two glasses of the plant extract solution (approximately 100-200 mg of the plant extract/glassful) was ingested daily.
  • topical application was performed using preparations described in Examples 10 and 11. Patients with respiratory diseases can also be treated with a plant extract inhalant.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

L'invention concerne des extraits végétaux obtenus à partir de Bactris, qui constituent un traitement thérapeutique efficace du diabète, du syndrome d'immunodéficience acquise, de l'influenza, de symptômes de refroidissement ordinaire, de l'emphysème pulmonaire, de la bronchite, de la polyomélyte, de la dégénérescence maculaire, du cancer, de la gingivite, de la dermatite, de la perte de cheveux, de l'hépatite, de l'herpès génital, du papillome et de l'asthme. La thérapie peut être administrée comme extrait aqueux de la plante ou de parties de la plante, ou comme poudre préparée à partir de la plante ou de parties de la plante.
PCT/US1999/012931 1998-06-09 1999-06-09 Extrait vegetal WO1999064029A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45550/99A AU4555099A (en) 1998-06-09 1999-06-09 Plant extract

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8863598P 1998-06-09 1998-06-09
US60/088,635 1998-06-09

Publications (1)

Publication Number Publication Date
WO1999064029A1 true WO1999064029A1 (fr) 1999-12-16

Family

ID=22212515

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/012931 WO1999064029A1 (fr) 1998-06-09 1999-06-09 Extrait vegetal

Country Status (2)

Country Link
AU (1) AU4555099A (fr)
WO (1) WO1999064029A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094299A1 (fr) * 2001-05-18 2002-11-28 Gbodossou Erick Vidjin Agnih Extraits de plantes medicinales dans le traitement des maladies diabetiques
US7780992B2 (en) 2002-12-08 2010-08-24 Tareq Abduljalil Albahri Antiviral medicament
CN104958507A (zh) * 2015-07-30 2015-10-07 济南邦文医药科技有限公司 一种治疗糖尿病合并下尿路感染的中药

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L. G. JOLY ET AL.: "ETHNOBOTANICAL INVENTORY OF MEDICINAL PLANTS USED BY THE GUAYMI INDIANS IN WESTERN PANAMA. PART I.", JOURNAL OF ETHNOPHARMACOLOGY., vol. 20, no. 2, 1987, ELSEVIER SCIENTIFIC PUBLISHERS LTD., IE, pages 145 - 171, XP002117644, ISSN: 0378-8741 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094299A1 (fr) * 2001-05-18 2002-11-28 Gbodossou Erick Vidjin Agnih Extraits de plantes medicinales dans le traitement des maladies diabetiques
US7780992B2 (en) 2002-12-08 2010-08-24 Tareq Abduljalil Albahri Antiviral medicament
CN104958507A (zh) * 2015-07-30 2015-10-07 济南邦文医药科技有限公司 一种治疗糖尿病合并下尿路感染的中药

Also Published As

Publication number Publication date
AU4555099A (en) 1999-12-30

Similar Documents

Publication Publication Date Title
Rajvaidhya et al. A review on Acacia Arabica-an Indian medicinal plant
US20100323045A1 (en) Extract formulation of opuntia ficus indica
WO2004084852A1 (fr) Formulation non toxique de soin dentaire aux herbes destinee a prevenir la formation de plaque et les gingivites
TW474815B (en) A process for preparing the galenic composition for prophylaxis and treatment of after effects due to excessive alcohol intake
AU710108B2 (en) Medicinal composition for diabetes
KR20040032920A (ko) 한입 버섯의 발효 생성물 및 그의 제조 방법과 용도
KR100831621B1 (ko) 혈당 강하용 식품 조성물
EP2567704A1 (fr) Composition issue de la médecine traditionnelle chinoise pour le traitement du diabète et méthode de préparation de ladite composition
CN104644759B (zh) 一种预防或/和治疗流感的保健茶及其制备方法
WO1999064029A1 (fr) Extrait vegetal
JP3962532B2 (ja) 抗糖尿病剤
JP7594748B2 (ja) 緑内障治療用組成物、緑内障治療用組成物の生産方法
EP1908474A2 (fr) Compositions physiologiquement actives basées sur des ingrédients actifs de basidiomycotine et araliaceae
CN100486636C (zh) 治疗牙齿敏感证的糊剂及其制备方法
EP1807098A1 (fr) Compositions a base d'herbes pour le traitement du diabete
US20200113958A1 (en) Compositions and Methods For Balancing Body Acidity and Relieving Body Over Acidity Symptoms and Strengthening the Immune Response
KR100894029B1 (ko) 인삼 꽃을 원료로 하는 당뇨의 예방을 위한 약학 조성물 및 치료를 위한 약학 조성물
KR20090126469A (ko) 혈당 강하용 생약 조성물
KR20100111088A (ko) 복합 생약 추출물을 유효성분으로 함유하는 당뇨병 또는 이로 인한 합병증의 예방 및 치료용 조성물
JPH08133983A (ja) アスパラス・リネアリス抽出物及び用途
WO2005077395A1 (fr) Composition physiologique active et son processus de production
JP2003073289A (ja) 活性酸素消去剤
KR100522532B1 (ko) 동충하초와 여주를 함유하는 혈당강하용 조성물
EP1641537A1 (fr) Formulation non toxique de soin dentaire aux herbes destinee a prevenir la formation de plaque et les gingivites
JP2002371001A (ja) 白内障の予防または治療剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase